What’s Trending?

Emergent BioSolutions, BARDA reach $628M deal to manufacture COVID-19 vaccine hopefuls kblankenship Mon, 06/01/2020 - 15:33 [...]
Mon, Jun 01, 2020
Source FiercePharma
Lynparza is the only PARP inhibitor to show patient benefit in a Phase III trial in this setting, says AZ [...]
Mon, Jun 01, 2020
Source PharmaTimes
Genetic ‘barcoding' in GP surgeries can identify men at higher risk of prostate cancer, researchers claim [...]
Mon, Jun 01, 2020
Source PharmaTimes
The NHS Race and Health Observatory will be hosted by the NHS Confederation [...]
Mon, Jun 01, 2020
Source PharmaTimes
The trial is unlikely to show a statistically significant improvement in invasive disease-free survival [...]
Mon, Jun 01, 2020
Source PharmaTimes
Due to the devastating worldwide impact of COVID-19, the illness caused by the SARS-CoV-2 virus, there has been unprecedented efforts by clinicians and researchers from around the world to quickly develop safe and effective treatments and vaccines. Given that COVID-19 is a complex new disease with no existing vaccine or [...]
Mon, Jun 01, 2020
Source WorldPharmaNews
ASCO: Has AstraZeneca finally found a place for long-plagued I-O candidate tremelimumab? chelfand Sun, 05/31/2020 - 16:58 [...]
Sun, May 31, 2020
Source FiercePharma
ASCO: Merck, Eisai pad case for liver cancer nod with Keytruda-Lenvima combo data chelfand Sun, 05/31/2020 - 14:03 [...]
Sun, May 31, 2020
Source FiercePharma
Pfizer's Ibrance misses shot at big new market with early breast cancer failure chelfand Sat, 05/30/2020 - 17:46 [...]
Sat, May 30, 2020
Source FiercePharma
Glucocorticoids are widely used in treating acute respiratory distress syndrome (ARDS) despite there being no indisputable scientific evidence of their effectiveness. The main reason seems to be that there is no effective treatment for ARDS patients on ventilators. The death rate of these patients differs between 30-40 percent depending on [...]
Fri, May 29, 2020
Source WorldPharmaNews
Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced the initiation of a global phase III, randomised, double-blind, multicentre study (REMDACTA) to evaluate the safety and efficacy of Actemra/RoActemra plus the investigational antiviral remdesivir, versus placebo plus remdesivir in hospitalised patients with severe COVID-19 pneumonia, in collaboration with Gilead Sciences, Inc. [...]
Thu, May 28, 2020
Source WorldPharmaNews
The investigational antiviral remdesivir is superior to the standard of care for the treatment of COVID-19, according to a report published today in The New England Journal of Medicine. The preliminary analysis is based on data from the Adaptive COVID-19 Treatment Trial (ACTT), sponsored by the National Institute of Allergy [...]
Wed, May 27, 2020
Source WorldPharmaNews
Sponsors submitting pediatric study plans should consider whether a product affects adults and children similarly when choosing an approach, the FDA says. [...]
Fri, Jan 16, 2015
Source FDANews